Biotech: Page 3
-
Daniel Tadevosyan via Getty Images
News roundupTessera gets sickle cell funding; Corvus shares slide on eczema data
The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.
By BioPharma Dive staff • Dec. 18, 2024 -
K_E_N via Getty Images
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
“Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The company plans to use its new funds to get to “proof of concept” for its medicines.
By Jacob Bell • Dec. 18, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Jacob Bell
Jazz to search for new chief as CEO plans retirement
Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its search within one year.
By Ned Pagliarulo • Dec. 16, 2024 -
Spencer Platt via Getty Images
Edgewise weighs fast approval path for muscular dystrophy drug
The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20% Monday.
By Ned Pagliarulo • Dec. 16, 2024 -
Daniel Tadevosyan via Getty Images
News roundup
Novo builds up manufacturing; Pepgen Duchenne trial put on hold
Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine Biosciences, Checkpoint and Galderma won new FDA approvals.
By BioPharma Dive staff • Dec. 16, 2024 -
Permission granted by Maat Pharma
Sponsored by MaaT PharmaCould the gut microbiome hold the key to fighting cancer?
MaaT Pharma is at the forefront of innovation in this field, striving to achieve the first-ever approval of a microbiome-driven immunomodulator in oncology.
Dec. 16, 2024 -
Bill Oxford via Getty Images
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that deny coverage of Qalsody because it’s “experimental and investigational.”
By Jacob Bell • Dec. 13, 2024 -
Daniel Tadevosyan via Getty Images
News roundup
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO
Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal. Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi.
By BioPharma Dive staff • Dec. 13, 2024 -
Courtesy of AbbVie
AbbVie to acquire Roche spinout Nimble in immune drug deal
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target of AbbVie’s injection Skyrizi.
By Ned Pagliarulo • Dec. 13, 2024 -
Permission granted by Editas Medicine
Gene editingEditas to lay off staff after search for sickle cell partner comes up empty
The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug candidate reni-cel.
By Ned Pagliarulo • Updated Dec. 13, 2024 -
Andrew Harnik via Getty Images
‘Research that’s desperately needed’: White House conference spotlights women’s health
“Sometimes the most under-hyped sectors are the best places to build very large businesses,” said one venture investor who attended Wednesday’s event.
By Delilah Alvarado • Dec. 12, 2024 -
Stock via Getty Images
Q32 Bio battered by study failure of immune drug
Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.
By Kristin Jensen • Dec. 11, 2024 -
Daniel Tadevosyan via Getty Images
News roundup
BenevolentAI restructures; Lilly preps $15B buyback program
The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.
By BioPharma Dive staff • Updated Dec. 17, 2024 -
Selvanegra via Getty Images
Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million from a broad syndicate.
By Gwendolyn Wu , Ned Pagliarulo • Dec. 11, 2024 -
Courtesy of UniQure
UniQure shares soar on chance of speedy approval for Huntington’s therapy
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an accelerated approval application.
By Jacob Bell • Dec. 10, 2024 -
Permission granted by Dimension
Emerging biotechDimension gets $500M to bankroll biotech’s convergence with tech
The firm’s co-founders claim to be pursuing a “contrarian” approach, building a team versed in both computing and life sciences and concentrating resources on a smaller number of bets.
By Ben Fidler • Dec. 9, 2024 -
Permission granted by Greater Phoenix Economic Council (GPEC)
Sponsored by Greater Phoenix Economic Council (GPEC)Why bioscience and healthcare innovators are looking to Phoenix
When Mayo Clinic was evaluating locations to build a biotechnology innovation hub, the Greater Phoenix region emerged as the ideal option.
Dec. 9, 2024 -
Michael M. Santiago via Getty Images
BioAge shares tumble after decision to halt obesity drug study
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following safety concerns.
By Gwendolyn Wu • Dec. 7, 2024 -
Daniel Tadevosyan via Getty Images
News roundup
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut spending and the U.S. PTO withdrew a controversial proposed patent rule.
By BioPharma Dive staff • Dec. 6, 2024 -
Permission granted by Atlas Venture
Emerging biotechAtlas doubles down on ‘disciplined’ biotech investing with latest fundraise
The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas grew too quickly, partner Bruce Booth wrote in a blog post.
By Kristin Jensen • Dec. 5, 2024 -
Courtesy of GSK
GSK taps a startup for shot at Alzheimer’s drug
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.
By Jacob Bell • Dec. 5, 2024 -
Permission granted by Nuvig Therapeutics
Nuvig pulls in $161M to make better immune drugs
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory conditions, starting with an antibody near Phase 2 testing.
By Gwendolyn Wu • Dec. 5, 2024 -
OGPhoto via Getty Images
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier treatment regimen.
By Kristin Jensen • Dec. 4, 2024 -
Daniel Tadevosyan via Getty Images
News roundup
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.
By BioPharma Dive staff • Dec. 4, 2024 -
Permission granted by Antag Therapeutics
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide drug data.
By Jonathan Gardner • Dec. 4, 2024
Previous
